High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma | Science Advances
Resiquimod (R848) | TLR7/8 Agonist | MedChemExpress
Frontiers | Anti-tumor Activity of Toll-Like Receptor 7 Agonists
Resiquimod - an overview | ScienceDirect Topics
Topical Resiquimod Protects against Visceral Infection with Leishmania infantum chagasi in Mice | Clinical and Vaccine Immunology
Topical Resiquimod Protects against Visceral Infection with Leishmania infantum chagasi in Mice | Clinical and Vaccine Immunology
Effects of treatments with resiquimod and/or PD-L1 blockade in Colon 26... | Download Scientific Diagram
Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01 - ScienceDirect
Pharmaceutics | Free Full-Text | TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases | HTML
Resiquimod - Wikipedia
Development of thermosensitive resiquimod-loaded liposomes for enhanced cancer immunotherapy. - Abstract - Europe PMC
High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung
Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo- controlled, double-blind phase IIa studies - Journal of Hepatology
The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-γ–producing cells - Journal of Allergy and Clinical Immunology
Development of resiquimod-loaded modified PLA-based nanoparticles for cancer immunotherapy: A kinetic study - ScienceDirect
Recent Advances in the Discovery and Delivery of TLR7/8 Agonists as Vaccine Adjuvants | ImmunoHorizons
Resiquimod is an effective therapy for early-stage CTCL. Changes from... | Download Scientific Diagram
High Capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of Lung Adenocarcinoma | bioRxiv
Recent clinical trends in Toll‐like receptor targeting therapeutics - Anwar - 2019 - Medicinal Research Reviews - Wiley Online Library
Resiquimod - an overview | ScienceDirect Topics
The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer | Nature Communications
Recent Advances in the Discovery and Delivery of TLR7/8 Agonists as Vaccine Adjuvants | ImmunoHorizons
Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies | Journal for ImmunoTherapy of Cancer | Full Text
Resiquimod (R-848) | ≥99%(HPLC) | Selleck | TLR agonist
